OR WAIT null SECS
The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more.
April 15, 2025
Video
Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.
March 17, 2025
Article
The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.
February 11, 2025
An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.
December 13, 2024
Despite having a lower risk of hospitalization, cardiovascular events, and mortality, patients with IgAN and FSGS had a higher risk of CKD progression.
December 11, 2024
Podcast
In the final segment of this episode, the discussion focuses on next steps for the PARASOL Initiative and its potential to transform FSGS drug development.
In part 2 of 4 from this episode, the discussion focuses on the groundbreaking work of the RADAR Registry and the PARASOL Initiative.
In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir.
This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.
October 31, 2024
Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.
October 30, 2024
Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.